AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie women's Health Portfolio [legacy through FY21] — Worldwide net revenues ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues
Latest, Q4 2021
223
Period ended Dec 31, 2021
Change on a year earlier
-12.9%
256 in Q4 2020
History
7 quarters
Since Q2 2020
Sources
7
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Women's Health Portfolio [legacy through FY21] — Worldwide net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2021 | Dec 31, 2021 | 223 | -12.9% | Form 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗ |
| Q3 2021 | Sep 30, 2021 | 202 | -15.5% | Form 8-K (abbv-20210930xexhibit991.htm, filed 2021-10-29) ↗ |
| Q2 2021 | Jun 30, 2021 | 191 | +29.9% | Form 8-K (abbv-20210630xexhibit991.htm, filed 2021-07-30) ↗ |
| Q1 2021 | Mar 31, 2021 | 180 | – | Form 8-K (abbv-20210331xexhibit991.htm, filed 2021-04-30) ↗ |
| Q4 2020 | Dec 31, 2020 | 256 | – | Form 8-K (abbv-20201231xexhibit991.htm, filed 2021-02-03) ↗ |
| Q3 2020 | Sep 30, 2020 | 239 | – | Form 8-K (abbv-20200930xex991.htm, filed 2020-10-30) ↗ |
| Q2 2020 | Jun 30, 2020 | 147 | – | Form 8-K (abbv-20200630xexhibit991.htm, filed 2020-07-31) ↗ |
Breakdown
What makes up women's health portfolio [legacy through fy21] — worldwide net revenues ($m)
- Women's Health Portfolio [legacy through FY21] — U.S. net revenues ($M)216 · Q4 2021
- Women's Health Portfolio [legacy through FY21] — International net revenues ($M)7 · Q4 2021
- Women's Health Portfolio [legacy through FY21] — Worldwide reported growth YoY (%)-12.7% · Q4 2021
- Women's Health Portfolio [legacy through FY21] — Worldwide operational (constant-currency) growth YoY (%)-12.8% · Q4 2021
- Lo Loestrin [legacy through FY21] — Worldwide net revenues ($M)128 · Q4 2021
- Orilissa/Oriahnn [legacy through FY21] — Worldwide net revenues ($M)39 · Q4 2021
- Other Women's Health [legacy through FY21] — Worldwide net revenues ($M)56 · Q4 2021
Cite this data
StockData. (2026). AbbVie Women's Health Portfolio [legacy through FY21] — Worldwide net revenues ($M) ($M), quarterly Q2 2020–Q4 2021 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ta_womens_ww
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.